Osteoclast inhibitors for knee conditions
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
1. A method of treating knee pain comprising:
a. selecting a patient having knee pain, and:
i. OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing, or
ii. pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS; and
b. administering an inhibitor of osteoclast activity selected from zoledronic acid, minodronic acid, risedronic acid, or neridronic acid to the patient.
2. The method of claim 1 , comprising selecting a patient having OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing.
3. The method of claim 1 , comprising selecting a patient having pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS.
4. The method of claim 2 , comprising selecting a patient having pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS.
5. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice.
6. The method of claim 5 , wherein the inhibitor of osteoclast activity is administered about every three months, or more frequently.
7. The method of claim 1 , wherein the patient experiences pain relief within about three months after the inhibitor of osteoclast activity is administered to the patient.
8. The method of claim 7 , wherein the patient experiences pain relief at least 24 hours after the inhibitor of osteoclast activity is administered to the patient.
9. The method of claim 1 , wherein the inhibitor of osteoclast activity is zoledronic acid.
10. The method of claim 1 , wherein the inhibitor of osteoclast activity is minodronic acid.
11. The method of claim 1 , wherein the inhibitor of osteoclast activity is neridronic acid.
12. The method of claim 1 , wherein the patient experiences a reduction in pain intensity—when using a 100 mm visual analog scale—of at least about 5.
13. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice over a period of at least four weeks.
14. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered once weekly for a period of six weeks.
15. The method of claim 14 , wherein the inhibitor of osteoclast activity is zoledronic acid, and the weekly dose is between about 25 mg and about 75 mg.